Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04918186 · ClinicalTrials.gov registry record · Phase 2
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
A Phase 2 study of Ovarian Cancer, sponsored by Canadian Cancer Trials Group.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 7
- Study locations
NCT04918186: Recruiting Phase 2 study of Ovarian Cancer, sponsored by Canadian Cancer Trials Group.
NCT04918186 is a Phase 2 study of Ovarian Cancer that is actively recruiting participants, run by Canadian Cancer Trials Group. The registered enrollment target is 60 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (92% lower). The trial reports 7 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04918186, a Phase 2 study of Ovarian Cancer, is actively recruiting participants, sponsored by Canadian Cancer Trials Group.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study is being done to answer the following question: What are the effects of a new drug or drugs on ovarian cancer? The pre-study screening may be done to test a sample of tissue for biomarkers to determine participation in the study.
Conditions Studied
Interventions
- DRUG Toripalimab
- DRUG Durvalumab
- DRUG BA3011
- DRUG BA3021
- DRUG ENB003
Study Locations (7)
British Columbia
- BCCA - Kelowna - Kelowna
- BCCA - Vancouver - Vancouver
Ontario
- Odette Cancer Centre - Toronto
- University Health Network - Toronto
Quebec
- CHUM-Centre Hospitalier de l'Universite de Montreal - Montreal
- The Jewish General Hospital - Montreal
Illinois
- The University of Chicago Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-05-03 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
What NCT04918186 shows while recruiting
NCT04918186 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 5 interventions - of which Toripalimab is the first listed.
NCT04918186 lists 7 locations in 4 states (British Columbia, Ontario, Quebec).
Frequently Asked Questions
What is clinical trial NCT04918186 about?
NCT04918186 is a clinical study titled "Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer". This study is being done to answer the following question: What are the effects of a new drug or drugs on ovarian cancer? The pre-study screening may be done to test a sample of tissue for biomarkers to determine participation in the study.
What is the current status of trial NCT04918186?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2022-05-03. Estimated completion is 2026-12-31.
What conditions does trial NCT04918186 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT04918186?
The interventions under investigation include: Toripalimab (DRUG), Durvalumab (DRUG), BA3011 (DRUG), BA3021 (DRUG), ENB003 (DRUG).
Who is sponsoring clinical trial NCT04918186?
This trial is sponsored by Canadian Cancer Trials Group, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04918186 being conducted?
This trial has 7 study locations across Illinois, British Columbia, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04918186's enrollment target sits among peer trials
60 193rd of 322 higher than 123 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI